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Summary of Cases
Subjects
Of patients with intractable atopic dermatitis (AD) who visited
the outpatient clinic of our hospital between January and
December 2000, 140 patients who consented to have photo-
graphs taken were selected as the subjects of this summary.
All patients met the criteria of AD proposed by Hanifin and
Rajka (1).
Treatment (Fig. 1)
It was first confirmed that conventional Western medical
therapy alone did not remit the symptoms.
Dietary change (Table 1) was recommended and introduced
on patient’s consent. When dietary instruction alone did not
heal the symptoms, Kampo remedy was added. This principle
was explained to the patients, and when consent was obtained,
the procedure was started.
Herbal remedy was selected based on the pathological state
and recorded. General hematology test, blood chemistry and
urinalysis were performed as far as possible to investigate the
presence or absence of adverse drug reactions.
Evaluation
There is still no evaluation system of the symptoms of AD
which has gained international acceptance, although several
scoring systems such as the scoring methods introduced by
Costa et al. (2), SCORAD (3) and SASSAD (4) have been pro-
posed for Western patients. We are not convinced that these can
be directly applied to Asian AD patients. Therefore, we used in
this series a criterion based upon the one proposed by the
National Research Group on AD of Japan (5) (Table 2). In our
criteria, the gravity of the disease is classified into four grades
(5–7) and the decreasing points from 4 to 0 are given to these
four grades ranging from the very severe to normal: very
severe   4, severe   3, moderate   2, mild   1, normal (with
no skin lesions)   0. The values before the initiation of
therapy and after  6 months were compared, and the degree of
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derivative work this must be clearly indicated.improvement in the clinical symptoms was judged. Three or
more points of improvement or persistence of exanthema-free
condition for  6 months were rated as ‘remarkable improve-
ment’, two points as ‘improvement’, one point as ‘slight
improvement’, no change in points or improvement requiring
oral steroid treatment within 6 months as “no change”, and a
minus point change was rated as “deterioration”. Patients who
had not been cured but stopped visiting the hospital within
6 months were defined as ‘drop out’. The evaluation results
were recorded and used for later therapy for individual patients.
The ratios of patients in whom the symptoms were alleviated
by dietary instruction alone and patients who required oral
herbal administration were investigated in these records. For
those patients whose clinical symptoms after 3 years were con-
firmed, the gravity of their disease state was evaluated on the
same scale as above to compare with the baseline condition.
For those whose symptoms we could not confirm, the results
were simply defined as ‘unknown’. For the adverse effects of
the therapy, not only skin symptoms due to AD, but any sub-
jective and objective abnormalities were carefully examined
and recorded.
Kampo Prescriptions
The following principles were applied in prescriptions:
(i) Byakko-ka-ninjin-to (8) and Oren-gedoku-to (8) for
erythema due to inflammatory congestion. Byakko-
ka-ninjin-to for heavy erythema with hotness with dry
skin. Oren-gedoku-to for erythema with heavy
congestion which is slightly edematous (9,10);
(ii) Eppi-ka-jutsu-to (8) for exudative eczema or heavily
edematous erythema (9,10); Ji-zuso-ippo (Zhi-tou-
chuang-yi-fang) (Table 3) (11–13) for exudative
eczema or impetigo on the scalp;
(iii) Jyumi-haidoku-to (Shi-wei-bai-du-tang) (Table 4)
(12–14) for folliculitis-like exanthema or pustule (9,10);
(iv) Shofu-san (8) for pruritus;
(v) Ku-Oketsu preparations (qu yu xue ji: drugs for over-
coming blood stagnation) for lichen and prurigo (9,10);
(vi) Yokuinin (8) and Unsei-in (8) for dryness and
desquamation (9,10);
(vii) Gorei-san (8) or Chorei-to (8) for water retention
(10,15);
(viii) Hochu-ekki-to (8) for Ki-kyo (qi xu: deficiency of Qi);
(ix) Keigai-rengyo-to (Jing-jie-lian-qiao-tang) (Table 5)
(12–14), Saiko-seikan-to (Chai-hu-qing-gan-tang)
(Table 6) (12–14) for constitutional detoxication, Ku-
Okestu preparations for Oketsu (yu xue: blood stag-
nation; syndrome caused by blood stagnation), for
example venous engorgement and dark-blue spots,
and for those with constipation (9,12,14);
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Table 1. Diet instruction
1. The principle food is rice. Boiled rice is recommended for breakfast.
Low-polished rice from which influence of contamination is eliminated as
far as possible.
2. For dishes other than the principle food, vegetables in season, fish and
shellfish/seaweed, soybean products.
3. Be careful not to ingest excess sweets, alcohol, coffee or juice.
4. Be careful not to ingest excess meats, fats or fatty oils (n-6 fatty acids in
particular).
5. Avoid processed food and additives.
6. Bland taste and homemade dishes are recommended.
7. Moderation in eating and pleasant meals with sufficient chewing.
Table 2. Classification of global clinical severity proposed by the National
Research Group on AD of Japan
Mild Only mild skin symptoms (slight erythema, dryness, scaling)
regardless of the affected area
Moderate With severe inflammatory lesions (erythema, papules,
erosions, infiltration, lichenification) over less than 10% of
the body surface area
Severe With severe inflammatory lesions over 10–30% of the body
surface area.
Very severe With severe inflammatory lesions over more than 30% of the
body surface area.
Figure 1. Methods.Of the 140 patients, 37 (26.4%) did not go proceed to Kampo
treatment (four of the ‘very severe’, 13 of the ‘severe’, 17 of the
‘moderate’ and three of the ‘mild’ cases). Of these patients, 21
dropped out for reasons other than changes in the disease con-
ditions (e.g. because of other time commitments), one ceased to
visit our hospital because the symptoms disappeared within 2
months without receiving Kampo therapy. On telephone contact
it was found that two among them were improved remarkably
with diet therapy alone, two were improved, one was slightly
improved, and four were unchanged (the other 12 patients were
‘unknown’, because contact could not be established). Among
those who were treated in our outpatient clinic for more than 6
months, there were eight patients whose symptoms were remit-
ted by change in dietary habit alone, with continuation of
Western conventional therapy (5.7% of total patients). For the
group of patients who did not wish to take Kampo medicine but
followed the diet recommendations during the observation
period, the diet change was slightly effective in seven patients
(5%), with no effect in one (0.7%) patient. After 3 years follow-
up, symptoms of those patients were remarkably improved in
eight patients, slightly improved in one and unknown in seven.
The remaining 103 patients (73.6%) proceeded to receive oral
Kampo preparations. The classification of these remaining
patients was: 44 ‘very severe’, 41 ‘severe’, 14 ‘moderate’ and
four ‘mild’ cases. After 6–12 months follow-up, remarkable
improvement was seen in 25 patients (17.9% of the total),
(x) Toki-shigyaku-ka-goshuyu-shokyo-to (Dang-gui-si-ni-
jia-wu-zhu-Yu-Sheng-Jiang-Tang) (Table 7) (12–14),
for chill (9,12,14);
(xi) Toki-shakuyaku-san (8) for chill accompanied by
water retention (9,12,14);
(xii) Kami-shoyo-san (8) or Saiko-ka-ryukotsu-borei-to (8)
for failure of autonomic nerve regulation (9,12,14).
Results (Tables 8–10)
Fifty-six male and 84 female patients, with ages ranging from
7 months to 53 years old, were treated. Among them, 48
patients were classified as ‘very severe’, 54 as ‘severe’, 31 as
‘moderate’ and 7 as ‘mild’. All of the ‘very severe’, 53 of the
‘severe’ patients, 27 of the ‘moderate’ patients and five of the
‘mild’ patients had been treated in other hospitals.
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Table 3. Components of Ji-zuso-ippo (Japanese; Zhi-tou-chuang-yi-fang in
Chinese) extract granules for ethical use (actions: dissolves eczema and
impetigo of the scalp)
Japanese Grams Scientific name Actions
Senkyu 3.0 Cnidii Rhizoma Promotes blood circulation
Sojutsu 3.0 Atractylodis Lanceae  Harmonizes water metabolism
Rhizoma
Rengyo 3.0 Forsythiae Fructus Anti-bacterial, anti-
inflammatory
Bofu 2.0 Ledebouriellae Radix Relieves itching, relieves pain
Kanzo 1.0 Glycrrhizae Radix Antitoxic, sedative, protect
digestive system
Keigai 1.0 Schizonepetae Spica Relieves pain, relieves itching,
anti-inflammatory
Koka 1.0 Carthami Flos Dissolves O-Ketsu, anti-
inflammatory
Nindo 0.5 Lonicerae Caulis et  Resolves purulent inflammation
Folium
Daio 2.0 Rhei Rhizoma Dissolves O-Ketsu, promotes
blood circulation, removes
constipation, anti-inflammatory
Table 4. Components of Jumi-haidoku-to (Japanese; Shi-wei-bai-du-tang in
Chinese) extract granules for ethical use (actions: resolves purulent
inflammation)
Japanese Grams Scientific name Actions
Saiko 3.0 Bupleuri Radix Sedative
Kikyo 3.0 Platycodi Radix Anti-inflammatory, resolves pus
Senkyu 3.0 Cnidii Rhizoma Promotes blood circulation
Bukuryo 2.0 Hoelen Removes excess body fluid
Bofu 2.0 Ledebouriellae Radix Relieves itching, relieves pain
Kanzo 1.0 Glycrrhizae Radix Antitoxic, sedative, protects
digestive system
Keigai 1.0 Schizonepetae Spica Relieves pain, relieves itching,
anti-inflammatory
Shokyo 1.0 Zingiberis Rhizoma Anti-emetic, protects gastric
mucosa
Dokkatsu 1.0 Aralliae Rhizoma et  Relieves pain
Radix
Bokusoku 3.0 Quercus Cortex Relieves pain, relieves itching,
anti-inflammatory, resolves pus
Table 5. Components of Keigai-rengyo-to (Japanese; Jing-jie-lian-qiao-tang
in Chinese) extract granules for ethical use (actions: anti-inflammatory,
reduces troubles by propionibacterium acnes, acts for immune regulation)
Japanese Grams Scientific name Actions
Ogon 1.5 Scutellariae Radix Anti-inflammatory, cools
Obaku 1.5 Phellodendri Cortex Anti-inflammatory
Oren 1.5 Coptidis Rhizoma Anti-inflammatory
Kikyo 1.5 Platycodi Radix Resolves sputum and pus, anti-
inflammatory
Kijitsu 1.5 Aurantii Fructus  Protects gastric mucosa
Immaturus
Keigai 1.5 Schizonepetae Spica Relieves pain, relieves itching,
anti-inflammatory
Saiko 1.5 Bupleuri Radix Sedative when smaller amount
Sanshishi 1.5 Gardeniae Fructus Sedative, Mild anti-inflammatory
Juk-jio 1.5 Rehmanniae Radix Moisters
Shakuyaku 1.5 Paeoniae Radix Relieves spasm, relieves pain,
anticonvulsive, relieves blood
stasis
Senkyu 1.5 Cnidii Rhizoma Promotes blood circulation 
resolves pus
Toki 1.5 Angelicae Radix Promotes blood circulation
Hakka 1.5 Menthae Herba Anti-inflammatory, sedative
Byakushi 1.5 Angelice Dahuricae Resolves pus, relieves pain
Radix
Bofu 1.5 Ledebouriellae  Relieves itching, relieves pain
Radix
Rengyo 1.5 Forsythiae Fructus Anti-bacterial, anti-inflammatory
Kanzo 1.0 Glycrrhizae Radix Antitoxic, sedative, protects
digestive systemfour, the aggravation in one coincided with exposure to toxic
chemicals used for remodeling of his house and the other three
all failed in changing their diets (because of the difficulty in
quitting sweets). Thus, we did not consider their conditions to
be aggravated by Kampo treatment. Kampo was therefore not
discontinued and the symptoms improved with better compli-
ance to the diet instructions. There were no severe adverse
effects due to Kampo treatment.
Overall Evaluation
Our approach was markedly effective in 25 patients (17.9% of
total), effective in 30 (21.4%) and slightly effective in 21
(15%). Our approach had no effect in 18 patients (12.9%).
After 3 years of follow-up, our approach was markedly effec-
tive in 38 patients (27.1% of total), effective in 29 (20.7%),
slightly effective in 14 (10%) and unknown in 10 (7.1%).
There were no serious adverse effects due to Kampo ses-
sions with no subjective or objective (laboratory examinations)
abnormalities.
Discussion
How Firm is the Evidential Basis for Conventional 
AD Therapy?
AD is a complex, multifactorial disease for which definite
guidelines of treatment have yet to be established. In principle,
the treatment mode will differ according to the grade of disease.
In mild cases, the mainstay of treatment is skin-care using
emollients. Dermatologists in recent years, however, have
debated hotly about how to treat those patients whose symp-
toms recur after this basic measure and also those who present
with higher-grade symptoms, either from the beginning or after
aggravation. The conventional wisdom among dermatologists
centers around a guideline such as follows (16,17):
1 As the first line, providing adequate explanation of the
nature of disease as well as advice on avoiding irrit-
ants, topical steroids for the skin lesion and oral anti-
histamines for sedation are recommended;
2 As the second line, removal of possible allergens and
ultraviolet therapy could be considered;
3 For the third line treatment of grave conditions, immuno-
suppressants such as systemic corticosteroids and cyclos-
porin A could be considered.
In one British guideline, Chinese herbal medicine is
included in the third-line treatment (16). In Japan, the con-
sensus guideline can be outlined as below:
1  As the first line, it is emphasized that the use of various
topical steroids should be fine-tuned according to the
degree of skin lesion, and the use of anti-histamines not
only for sedation but to directly reduce pruritus is
accepted, in addition to guideline 1, above.
2  As the second line, systemic use of anti-allergic drugs
with anti-cytokine properties are suggested in addition to
guideline 2, above, but ultraviolet therapy is reserved for
third line.
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Table 6. Components of Saiko-seikan-to (Japanese; Chai-hu-qing-gan-tang
in Chinese) extract granules for ethical use (actions: reduces recurrence of
tonsillitis, eczema, or inflammation, anti-allergic)
Japanese Grams Scientific name Actions
Ogon 1.5 Scutellariae Radix Anti-inflammatory, cools
Obaku 1.5 Phellodendri Cortex Anti-inflammatory
Oren 1.5 Coptidis Rhizoma Anti-inflammatory
Kikyo 1.5 Platycodi Radix Resolves sputum and pus,
anti-inflammatory
Karokon 1.5 Trichosanthis Radix Anti-inflammatory
Goboshi 1.5 Arctii Fructus Anti-inflammatory, resolves pus
Saiko 2.0 Bupleuri Radix Sedative when smaller amount
Sanshishi 1.5 Gardeniae Fructus Sedative, mild anti-inflammatory
Juku-Jio 1.5 Rehmanniae Radix Moistens
Shakuyaku 1.5 Paeoniae Radix Relieves spasm, relieves pain,
anticonvulsive, relieves blood
stasis
Senkyu 1.5 Cnidii Rhizoma Promotes blood circulation,
resolves pus
Toki 1.5 Angelicae Radix Promotes blood circulation
Hakka 1.5 Menthae Herba Anti-inflammatory, sedative
Rengyo 1.5 Forsythiae Fructus Anti-bacterial, anti-inflammatory
Kanzo 1.5 Glycrrhizae Radix Antitoxic, sedative, protects
digestive system
Table 7. Components of Toki-shigyaku-ka-goshuyu-shokyo-to (Japanese;
Dang-gui-si-ni-jia-wu-zhu-yu-sheng-jiang-tang in Chinese) extract granules
for ethical use (actions: reduces chill, promotes blood circulation)
Japanese Grams Scientific name Actions
Taiso 5.0 Zyzyphi Fructus Antitoxic, strengthens digestive
system
Keihi 3.0 Cinnamoini Cortex Promotes blood circulation
Shakuyaku 3.0 Paeoniae Radix Relieves spasm, relieves pain,
anticonvulsive, relieves blood
stasis
Toki 3.0 Angelicae Radix Promotes blood circulation
Mokutsu 3.0 Akebiae Caulis Removes excess body fluid
Kanzo 2.0 Glycrrhizae Radix Antitoxic, sedative, protects
digestive system
Goshuyu 2.0 Evodiae Fructus Anti-emetic
Saishin 2.0 Asiasari Radix Relieves pain
Shokyo 1.0 Zingiberis Rhizoma Anti-emetic, protects gastric
mucosa
improvement was seen in 30 (21.4%), slight improvement in 21
(15%), unchanged in 14 (10%) and aggravation of condition in
four (2.9%). There were withdrawals: seven patients were
unassessable because they could not visit our clinic, one was
improved within 6 months but subsequent attempts at contact
failed and one became unassessable because of heavy treatment
for complications. Among these 103 patients, the number
treated by Kampo by previous physicians was 22 (15.7% of
total), among whom our Kampo treatment was markedly to
slightly effective in 19 patients (13.6%). All four patients with
aggravated conditions complained of mental stress: of theseeCAM 2004;1(2) 149
Table 8. The evaluation results after 6 months to one year follow-up
Evaluation Kampo ( ) Kampo (+)
patients % (group) % (total)  patients % (group) % (total)
(n = 37) (n = 103)
remarkable improvement 8 21.6 5.7 25 24.3 17.9 
improvement 0 0.0 0.0 30 29.1 21.4
slight improvement 7 18.9 5.0 21  20.4 15.0
no change 1 2.7 0.7 14 13.6 10.0
deterioration 0 0.0 0.0 4 3.9 2.9
drop out 21 56.8 15.0 9 8.7 6.4 
Table 9. Comparison between groups with or without previous Kampo among patients who received oral Kampo
prescriptions
Evaluation previous Kampo ( ) previous Kampo (+)
patients % (group) % (total*)  patients % (group) % (total*)
(n = 81) (n = 22)
remarkable improvement 17 21.0 12.1 8  36.4 5.7
improvement 23 28.4 16.4 7  31.8 5.0
slight improvement 17  21.0 12.1 4  18.2 2.9
no change 12  14.8 8.6 2  9.1 1.4
deterioration 3 3.7 2.1 1  4.5 0.7
drop out 9  11.1 6.4 0  0.0 0.0
*Total, 140, includes 37 patients without administration of Kampo formula.
Percentages may not sum to 100, because of rounding.
Table 10. The evaluation results after 3 years follow-up*
Evaluation Kampo ( ) Kampo ( )
patients % (group) % (total)  patients % (group) % (total)
(n = 37) (n = 103)
remarkable improvement 8 21.6 5.7 38 36.9 27.1 
improvement 0 0.0 0.0 29 28.2 20.7
slight improvement 1 2.7 0.7 14  13.6 10.0
no change 0 0.0 0.0 3 2.9 2.1
deterioration 0 0.0 0.0 0 0.0 0.0
unknown 7 18.9 5.0 10 9.7 7.1
drop out 21 56.8  15.0 9  8.7 6.4 
*Percentages may not sum to 100, because of rounding.3  For the third line, in addition to guideline 3, above, anti-
mycotic agents are suggested for possible mycosis in the
intestine, ultraviolet therapy, psychotherapy and anti-
allergic treatment for metals are recommended (18,19).
Systemic use of immunosuppressive agents is not highly
recommended in Japan, and topical use of tacrolimus by
professional dermatologists with informed consent has
been recommended (20).
Even in Japan, the status of Kampo medicine in this system
has not been settled yet.
To date, however, there has been little solid evidential basis
for either of the approaches above as systematic strategies, at
least on the standard model of evidence-based-medicine
(EBM). The number of randomized control trials (RCT) on the
efficacy of each agent seems to be increasing, but they are still
problematic. This is because it is difficult to define the proper
endpoint for this disease, and also any clinical trials for AD
with a duration of less than 2 years could be of questionable
validity. For example, Hoare et al. (16) analyzed 1165 RCTs to
evaluate various modalities for prevention and treatment of
AD. They concluded that oral cyclosporin, topical steroids,
psychological approach and ultraviolet therapy have been
shown to have positive evidence of efficacy. We think their
conclusions are not at odds with the clinical experience of a
majority of dermatologists. However, both endpoint and trial
periods vary among these studies; therefore, we cannot accept
those authors’ evaluation without reservation. Some of the
above treatments are easy to prove effective by conventional
RCT when their short-term effects on skin symptoms only are
evaluated. Experienced dermatologists are well aware of the
danger of long-term use of those agents which are effective in
the short-term and are targeted for the skin symptoms alone.
Specifically, we suspect that oral immunosuppressive agents
may even be proven harmful by RCT if used chronically by
taking skin symptoms as the sole endpoint.
Topical corticosteroids, first introduced in the early 1950s,
have since remained the mainstay of current AD therapy. A
small amount of high-quality evidence is now available
(7,16,21–38). However, as they are superficially so effective,
particularly for those patients whose trigger factor is one
which can be easily removed, and also inflammation is tempor-
ary, both physicians and patients tend to become dependent
on them. When development of more severe lesions with atyp-
ical symptoms occurs, for example, flexural eczema in the
limbs turned into facial intractable erythema, topical cortico-
steroids would become less effective. The present EBM is still
not subtle enough to address such problems as changed effect
of one agent according to the situation of an individual patient
during the chronic course of a complex disease. For example,
Hoare et al. (16) stated that they could find no RCT evidence
to support different approaches to using topical corticosteroids
such as comparing shorter bursts of strong preparations versus
longer-term treatment with weaker preparations.
This evidential situation is similar for other conventional
drugs. For example, although anti-histamines are convention-
ally employed with topical corticosteroids as the first-line
therapy for AD, there seems to be little high-quality evidence
available to prove their efficiency in AD itself (39–60). As to
immunosuppressive agents represented by cyclosporin, evid-
ence for their long-term benefits are still lacking, although
they have been used for AD patients on the basis of their short-
term effects (61–64). Recently, topical calcineurin inhibitors,
namely tacrolimus and pimecrolimus, have been added to the
repertoire in first line therapy (65), as they seem to be free
from the adverse effects seen when corticosteroids were
used protractedly and they also appear to actually inhibit the
progress of the disease (66–69). However,we agree to the recom-
mendation for their careful use, as their long-term efficacy and
adverse effects have not been elucidated yet (70).
Thus, there are two major pitfalls in applying the standard
RCT approach to AD, namely, duration of the trial and end-
point. As pointed out above, short-term effectiveness may con-
vert to long-term harm, and skin symptoms may not even be
taken as the true endpoint of AD, but only as one of the surro-
gate endpoints. Indeed, some groups have already discussed
the issue that data from large scale RCTs do not necessarily
provide evidence useful for actual clinical practice in dealing
with AD patients (38,71). In addition, there is one more import-
ant issue in AD when RCT is to be planned and evaluated. It is
that AD may not even represent a single disease entity, but may
instead represent common skin expressions of different patho-
physiological states. As randomization is only possible for a
homogeneous population of patients, taking skin symptoms as
the target would be misleading if the underlying conditions
were heterogeneous.
Although the conventional approach utilizing drugs such as
those listed above brings many patients’conditions under con-
trol, there are definite subgroups of patients who become
intractable by this approach. No serious attempt seems to have
been made to statistically estimate the actual number of such
patients, because it is difficult to judge whether those patients
should be regarded as ‘intractable cases’or just treatment fail-
ures. But experience of professional dermatologists would
settle around the figure of as much as 40% of AD patients in
this category, and there have been several reports showing that
similar percentages of patients turn to non-conventional CAM
therapies (72–74).
Such a situation may even allow us to cast doubt on the con-
ventional guideline itself, especially the ‘third line’ agents
listed above. Although we would not side with those ‘extrem-
ists’ who claim that the very use of systemic corticosteroids
and immunosuppressant drugs or even chronic use of topical
steroids have caused the spread of intractable AD over the last
few decades, we should admit at the same time that there is no
definite evidence that disproves their claims. Thus, although
we ourselves have generally sided with the consensus, or con-
ventional, guideline, we are by no means satisfied with its evid-
ential basis. We would not, at least for the moment, abandon
topical corticosteroids as a first line drug (along with diet) for
AD patients. But it does not mean that we take it as a ‘central’
or ‘mainstay’remedy that should come before everything else.
Topical steroids should be seen as one of the first options to
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indefinitely. Thus, we roughly agree that the conventional
guideline has evidential basis up to the first and the second line
modalities, but no more. We would like to combine the guide-
lines 1 and 2 above as recommended ‘first-line’ therapy for
AD. We are in opposition to the easy use of systemic cortico-
steroids and immunosuppressive agents. They should not even
be regarded as the second-line therapy, but be reserved as the
last resort to be used in the short term.
How Should Kampo be Viewed as Treatment 
Modality for AD?
First or Second Line?
We believe that we have established that our ‘Diet and Kampo’
approach can bring cure for  50% of patients considered to be
intractable with the conventional approach. Since we agree that
the conventional approach, especially topical steroids, is effec-
tive for the majority of AD patients in the short term, we opt to
include it as first-line therapy along with diet change, and thus
Kampo is reserved as a second-line regimen, to replace sys-
temic use of corticosteroids and immunosuppressive agents.
We think our approach can therefore be adopted and tried in the
West. On the other hand, as mentioned above, in Japan (and
other Asian countries) there are ‘fundamentalist’Kampo physi-
cians who contend that AD can be cured with Kampo alone.
However, from our own experience, Kampo alone as a first-line
regimen seems no more effective than the standard first-line
therapy, though again we should be cautious about individual
differences: there seem to be a subgroup of patients for whom
Kampo is more effective as the single first-line regimen. The
view that Kampo is not a magic bullet is partially supported by
the case studies presented above, which show that a substantial
proportion of patients who visit our clinic have failed with
Kampo. We would thus not suggest that large-scale standard
RCT should be planned to compare the effect of any single spe-
cific Kampo formula against topical corticosteroids in a hetero-
geneous population of patients with AD.
Although much attention has recently been focused on
Kampo herbal medicine for AD (6,8–11,14,15,75–102), there
are only a few reports examining the efficacy of Kampo in a
first-line treatment setting, as reviewed by Armstrong and
Ernst (97). Sheehan et al. (98–100) reported the usefulness of
the composite herbs of Zemaphyte® by a randomized, double-
blind cross-over trial. However, a subsequent trial by Fung
et al. (102) failed to show its superiority over placebo. These
reports are not very surprising to us, though we believe Kampo
alone can be at least more effective than placebo. Zemaphyte’s®
composite herbs include Bofu (Ledebouriella seseloides) and
other anti-pruritic herbs, and Jio (Rehmannia glutinosa) and
other anti-inflammatory and anti-congestive herbs. Their phar-
macological actions are being elucidated by modern Western
techniques (103–108). Some of these components overlap with
those in our formulae, but generally we regard them as alleviat-
ing agents for superficial symptoms, so we do not expect them
to be more useful than topical steroids and oral anti-histamines
as first-line drugs in treating those patients who could well be
cured by conventional treatment.
We have not been able to find any previous reports in the
literature where Kampo has been systematically used specifi-
cally as second-line treatment for those in whom the standard
treatment has failed. Our report seems to be the first to show
its actual effectiveness in this setting and also to show that
Kampo treatment can smoothly complement conventional
modes of therapy.
Kampo Paradigm and AD
As seen in the case studies, Kampo therapy for AD patients is
not straightforward. It is the rule rather than the exception that
we have to resort to plural formulae before bringing a patient’s
conditions under control. The Kampo remedies we use include
Shofu-san, Ji-zuso-ippo and Eppi-ka-jutsu-to. These remedies
are for the treatment of symptoms exhibited on the body sur-
face, but very often we use such formulae as Hochu-ekki-to,
intending to simultaneously improve patients’ general condi-
tions. Even for the same disease entity in the Western concept
of medicine, we prescribe different herbal preparations for
individual patients according to the overall presentation of
each patient, and the prescription is changed with changes in
the main pathology of the patient during the course of treat-
ment. This approach of fine-tuning using multiple formulae is
the major cause of difficulty in performing double blind RCT
to investigate the usefulness of herbal preparations for a
complex disease such as AD.
Since the pathogenesis of the disease itself is still obscure, the
conventional treatment is symptomatic in principle. Aside from
the use of anti-histamines for pruritus, the very use of steroids
and other immunosuppressive agents is aimed at suppressing
manifestations of inflammatory reactions and not at correcting
the underlying disorders. Simply put, it is analogous to the situ-
ation of early 20th century medicine against influenza, when the
very existence of viruses was unknown, while aspirin had been
used to suppress fever with reasonable success. This symptom-
oriented approach is no doubt reasonable in Western analytical
medicine, where no specific agent should or could be employed
to radically cure disorders of which we do not have enough
pathogenetic knowledge. However, such a strategy will become
problematic if adverse effects of the drugs used to suppress
superficial symptoms override correction of the underlying con-
ditions. Those conditions would include putative abnormality in
the immune system, failure of the autonomic nervous regulatory
functions and imbalance of the endocrine system, all of which
have been implicated for AD. The fact that Kampo with diet
therapy can bring about cure for many of those patients refrac-
tory to the conventional treatment suggests, though of course
does not prove, that the Kampo regimens are affecting not the
superficial symptoms but the underlying pathogenetic condi-
tions of these patients. While there is no conventional treatment
aimed at these underlying conditions, Kampo should be con-
sidered seriously as a treatment modality directed at an alternative
target. In doing so, clinical trials should be designed so as not to
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the short-term by steroids or immunosuppressive agents.
Besides the difference of treatment target as above, modern
Western medicine can be supplemented in another way by the
Kampo approach. That is, the long-term view on the patient as
an individual. Experienced dermatologists are aware that there
are several subgroups in AD patients, and various subsets and
temporal phases in its clinical manifestations. For example,
patients having psychological problems are quite different from
those with dietary habit problems. Likewise, the disease phase
in one individual patient is different whether inflammatory
reactions are the main manifestation or not. When we resort to
Kampo therapy, we choose from a wide variety of Kampo
repertoires those which we consider best for each individual
patient in certain specific conditions. These ‘conditions’ are
called ‘Sho’ in Kampo (12). We would admit that identifying
Sho is still rather intuitive, and more art than science at present.
One way for Kampo therapy to become more universally applic-
able is to develop more analytical descriptions of the patient’s
Sho for which only certain kinds of Kampo formulae could be
agreed to be used by experienced Kampo physicians. Double-
blind placebo controlled trial could become valid if Sho
descriptions could become more objective.
How Should Kampo be Integrated Into the Treatment
Strategy for AD?
Proposal: An Alternative Guideline
Based on the presentation and discussions above, we would
like to propose an interim alternative guideline for AD therapy
with some proposal for its evaluation by clinical trials. Our
alternative guideline is as below:
1. First, discuss with patients their general lifestyle, espe-
cially their diet. Propose to the patient that AD could
be cured ‘from within’, or by returning to a better state of
his/her mind–body, by, specifically, returning to healthier
dietary habits. Try to ask the patient to understand that
skin inflammation is sometimes an expression of a deeper
imbalance of his/her mind–body if there are no obvious
allergens or irritants. Try to provide good supportive care
for those patients with psychological problems.
2. Try topical steroids, tacrolimus ointment and emollients
to alleviate the skin symptoms. Try anti-histamines in
cases of severe pruritus. Try Kampo regimens if these
regimens fail.
3. Systemic administration of corticosteroids and immuno-
suppressant drugs should be reserved only for patients
with whom all the above measures have failed. Even
when they are to be introduced, they should be used only
for very limited duration in order to avoid any adverse
effects due to protracted use. Kampo can be continued
with these agents as several Kampo prescriptions can
alleviate adverse effects of these agents.
Essentially, this is a proposal to place Kampo as the second-
line treatment before systemic corticosteroids and immuno-
suppressant agents. Recent epidemiological evidence has
established the long suspicion that use of systemic cortico-
steroids increases the incidence of malignancy (109).
We would like to add that we have used Kampo for many
patients as first-line with reasonable success, and so after fur-
ther studies we may even place it as a first-line therapy. But,
for the time being, we would recommend the above guidelines,
as conventional therapy is effective in many cases if carried out
within the framework of psycho-physical care and serious
improvement in lifestyle to avoid trigger factors. Also, we
would like to point out that Kampo herbs are limited resources,
abuse of which will deprive future patients of opportunities to
benefit from them.
How to Evaluate the Alternative Guideline Using Kampo?
We think the most important but problematic aspect of Kampo
therapy proposed above is that Kampo presupposes the use of
plural formulae for each individual patient. Kampo therapy is
not a treatment using a single mono-component drug but a
treatment ‘session’ using various multi-component herbs.
The most appropriate method to evaluate the efficacy of such
a guideline would be modified ‘N-of-1’trial (110–116), where
the effect of a Kampo ‘session’ by one physician is evaluated
for one individual patient against placebo. The trial will com-
prise several sequential periods during which Kampo sessions
using real herbs or placebo are alternated, in a randomized
double-blind manner. We have yet to start such a trial, because
there are still no good placebo preparations for different spe-
cific Kampo formulae. But we are considering the introduction
of capsule formulations to actually carry out such a trial.
A Further Proposal of Trial Based on the 
Kampo Paradigm
We have shown in the case series that our Kampo formulae are
not necessarily prescribed for any specific ‘symptoms’of AD in
the modern Western sense. We have also suggested that AD may
be seen not as a single disease entity, but may be regarded as het-
erogeneous pathophysiological conditions sharing several char-
acteristic skin symptoms. If that were really the case,AD patients
should be classified into several subgroups. Such classification
will be established based on Western scientific pathophysiology
in the future. But even without having such a ‘scientific’classifica-
tion, we would like to propose here that there seems to be one
rather distinct subgroup in AD patients from the viewpoint of
Kampo. It is a group of patients who exhibit the Sho we call in
Kampo O-Ketsu (‘dirty blood’). These patients are usually obese
with high fat/caloric intake (the ‘fried potatoes’ group). We
hypothesize that AD may develop in these people when they
reach the stage exhibiting ‘O-Ketsu’ Sho. For these patients, we
believe, such formulae as Keishi-bukuryo-gan are effective with
diet changes. Standard RCT may even be designed to check the
effect of one single Kampo formula against placebo if such a
classification of patients according to Sho could be introduced.
Such a trial design of RCT is, however, the exception and not the
rule for Kampo treatment, as it is a rule and not the exception that
Sho changes during the period of treatment.
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the present report is systematized. For example, the guideline
above is applied first to all patients, those who failed by the
first-line treatment are randomized into two groups where the
only difference is presence or absence of Kampo treatment.
In such a design, not only the symptoms but also quality of
life and necessity of corticosteroids should be added as evalu-
ation points.
As pointed out before, not only the length of trial period but
the timing at which the effect is evaluated is crucial in assess-
ing any treatment modes for AD. For Kampo herbs in particu-
lar, with rare exceptions such as Byakko-ka-ninjin-to, it takes
months for their effects to become apparent. Evaluation of the
effects of any agents tried for AD is not only important for
confirming their real efficacy and safety but also from the
standpoint of patients themselves, for whom short-term disap-
pearance of symptoms does not mean much. We have so far
not discussed the detail of the diet therapy essentially accom-
panying our Kampo therapy. But long-term evaluation is par-
ticularly important for our Kampo diet therapy, which, unlike
that of simple removal of allergens, takes years for its effects
to become apparent. Thus, we propose that in clinical trials
of any agents for AD, their effects should be evaluated after
3 years as a minimum. We are convinced that Kampo and diet
approach is not inferior to any other modalities if the long-term
viewpoint is taken in evaluation.
The Art of Kampo
In proposing such a guideline and plan for clinical trials, we
would like to make a final remark of caution. We have
provided evidence in this Review that Kampo therapy is effec-
tive only when administered by experienced practitioners.
Therefore, the guideline above would also state that Kampo
sessions should be managed by an expert. Traditional Kampo
therapy, being like an art or craft, unlike the science and tech-
nology of modern Western medicine, is hard to gain expertise
in, since it depends not on objective measures and techniques
but on subjective observations, experience and oral instruction
by Kampo masters. In Japan, a new generation of doctors is
now emerging, who are educated in modern medical schools
but learned Kampo from existing masters. These doctors, our-
selves included, are trying to integrate modern and traditional
approaches. The consensus being formed is that diagnosis
should be fully based on modern analytical science, but in the
treatment we should introduce Kampo upon understanding its
pharmacological effects and patients’ pathophysiological
conditions both in terms of modern and traditional medicine.
Thus, as seen above, we use Kampo on symptoms understood
in terms not only in modern Western medicine but also in tra-
ditional Kampo terms. For example, we use Hochu-ekki-to to
enhance Ki (Qi) for those patients who are in the condition
(Sho) of Ki-kyo (‘hollow spirit’). As can be easily understood,
while there is still no objective parameter to measure Ki in
modern medicine, this intuitive approach has great danger of
being abused. Expertise is the fundamental condition for the
sound practice of Kampo. We do not wish to be mystical in
stating this, however, since expertise of doctors is a definite
determinant of cure in any medical practice, regardless of its
Eastern or Western origins. In addition, even in the Kampo
repertoires, there are several formulae which do not require
much mystical insight in prescribing them: for example,
Hochu-ekki-to can be rather safely used by non-expert physi-
cians to ‘encourage’ those AD patients who are discouraged
(hollow-spirited). Some of Kampo Sho is not mystical at all,
but even commonsensical. From a different viewpoint, we
would also like to emphasize that an element of art in medicine
becomes inevitable whenever the very nature of the disease
treated is mysterious. AD is one representative example of
such disorders. In treating a ‘mysterious’disease like AD and,
for example, many of the autoimmune diseases, good intuition
about the individual patient’s changing conditions is still an
essential prerequisite for a clinical physician to provide bene-
ficial support to him/her. We contend that artful Kampo treat-
ment is a strategy to be seriously considered for AD patients.
We would welcome any Western dermatologists who wished
to visit our clinic to learn Kampo with us and attain the mini-
mum level of expertise. Widespread application of the art of
Kampo would make it possible to test its actual effectiveness
by such trial methods as proposed above at multiple institu-
tions around the world.
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